The Medicines and Healthcare products Regulatory Agency (MHRA) has revisited advice it issued in 2013 on switching between oral antiepileptic drugs from different manufacturers.1 The new advice, published in the MHRA's Drug Safety Update, follows a review by the Commission of Human Medicines in 2016, which was prompted by feedback and requests for clarification on the 2013 advice from patients and healthcare professionals.

The core advice from 2013 has been updated with some refinements and revisions.1,2 For example, …